Abstract Hypertension is a major risk factor for cardiovascular disease, with cardiovascular disease being the leading cause of hypertension-related mortality. Systolic blood pressure is superior to diastolic blood pressure when predicting cardiovascular risk. Despite this, diastolic blood pressure still plays a significant role in calculating risk, particularly of ischaemic heart disease in older populations and stroke in younger populations. Hypertension frequently occurs in the presence of other cardiovascular risk factors, including dyslipidaemias, hyperglycaemia, and raised body mass index. Scoring tools, such as QRISK3 and SCORE, can be used to calculate cardiovascular risk in the context of a patient’s age, lifestyle, and comorbidities. Reducing elevated blood pressure can lead to a reduction in cardiovascular risk, with recent studies advocating for a target systolic blood pressure of less than 130 mmHg.
Long COVID (LC) or post-acute sequelae of SARS-CoV-2 infection (PASC) is defined as ongoing, relapsing or new symptoms/conditions persisting after an acute COVID-19 infection. Given the potential role of oral anticoagulants (OAC) in treating thrombotic sequelae of LC/PASC, we investigated whether prevalent OAC use at the time of acute COVID-19 infection was associated with reduced development of LC/PASC. Retrospective cohort study within the TriNetx network. The primary cohort was defined as adults with a confirmed diagnosis of COVID-19. We defined OAC users as those who had received OACs (either direct-acting OACs [DOACs] or vitamin K antagonists [VKA]) in the preceding 3-months and non-users as those without OAC use within the previous 12-months. The primary outcome was a composite of 9 features associated with LC/PASC We identified 38,409 DOAC users, 19,243 VKA users, and 2,329,771 non-OAC users with acute COVID-19 infection. After successful propensity score matching (PSM), we found an increased risk of LC/PASC features in those receiving DOAC compared to non-OAC (HR [95% CI] 1.50 [1.35 to 1.68], p < 0.0001), and in VKA users compared to non-OACs (HR [95% CI] 1.98 [1.78 to 2.20], p < 0.0001), while DOAC users were at reduced risk compared to VKA users (HR [95% CI] 0.71 [0.62 to 0.81], p < 0.0001). We found no evidence that prevalent OAC at the time of acute COVID-19 infection was associated with reduced risk of LC/PASC. Further work is needed to understand whether there is a role for OAC therapy in the management of LC/PASC.
Abstract Funding Acknowledgements Type of funding sources: None. Background There are limited data on whether there is an association between hospitalisation with dental periapical abscess and new-onset atrial fibrillation (AF) which is independent of main cardiovascular risk factors. Purpose To investigate whether there is an association between hospitalisation with dental periapical abscess and new-onset AF. Methods A retrospective cohort study from a national database of patients hospitalised in 2013 (3.4 million patients) with at least five years of follow up, unless deceased. International Classification of Diseases (ICD) codes were used to compare the risk of developing new-onset AF for adults with and without dental periapical abscesses using univariate and multivariable analysis and hazard ratios (HR). Results In total, 4,693 patients classified as having dental periapical abscess, 435 (9.27%) developed AF, compared to 326,241 (10.69%) without dental periapical abscess over a mean follow-up of 4.8 ± 1.7 years. Multivariable analysis indicated that dental periapical abscess acted as an independent predictor for new onset AF (p &lt; 0.01). Conclusions An increased risk of new onset AF was identified for individuals hospitalised with dental periapical abscess. Careful follow up of patients with severe, acute dental periapical infections are needed for incident AF, as well as investigations of possible mechanisms linking these conditions. Predictors of new-onset AF during FU Univariate analysis Multivariate analysis HR, 95%CI P HR, 95%CI P Age, years 1.077 (1.076-1.077) &lt;0.0001 1.076 (1.075-1.076) &lt;0.0001 Gender (male) 1.640 (1.629-1.651) &lt;0.0001 1.0498 (1.487-1.509) &lt;0.0001 Hypertension 2.849 (2.829-2.869) &lt;0.0001 1.114 (1.487-1.509) &lt;0.0001 Diabetes mellitus 1.951 (1.935-1.968) &lt;0.0001 1.106 (1.096-1.116) &lt;0.0001 Heart failure 3.893 (3.857-3.930) &lt;0.0001 1.434 (1.416-1.452) &lt;0.0001 Ischaemic stroke 2.289 (2.23902.340) &lt;0.0001 1.140 (1.114-1.165) &lt;0.0001 smoker 0.903 (0.891-0.917) &lt;0.0001 1.052 (1.036-1.069) &lt;0.0001 Liver disease 1.141 (1.119-1.164) &lt;0.0001 1.082 (1.059-1.105) &lt;0.0001 Previous myocardial infarction 2.128 (2.082-2.176) &lt;0.0001 0.903 (0.880-0.926) &lt;0.0001 Inflammatory disease 1.036 (1.020-1.052) &lt;0.0001 0.978 (0.964-0.994) 0.005 Cognitive impairment 2.368 (2.326-2.410) &lt;0.0001 0.821 (0.807-0.836) &lt;0.0001 Illicit drug use 0.288 (0.263-0.317) &lt;0.0001 0.940 (0.855-1032) 0.19 Dental periapical abscess 0.855 (0.778- 0.939) 0.001 1.107 (1.008-1.216) 0.03 At least 5 years of follow-up (mean follow-up 4.8 ± 1.7 years). Abstract Figure. Flow Chart of the study patients
Objective: To compare the risk of major bleeding overall and stratified by CHA2DS2-VASc score, among non-valvular atrial fibrillation (NVAF) patients initiating apixaban and warfarin. Methods: This is a retrospective cohort study using MarketScan® Commercial and Medicare supplemental data. NVAF patients newly prescribed warfarin or apixaban with ≥1 year of baseline period were identified (study period: 01JAN2012-30JUN2015). Patients were stratified by CHA2DS2-VASc score, an indicator of stroke risk, where patients with a score <2 and ≥2 were considered low and high risk for stroke, respectively. Major bleeding was defined as bleeding requiring hospitalization (based on the first listed ICD-9-CM diagnosis code). Cox proportional hazards models were used to estimate the hazard ratio (HR) of major bleeding risk, adjusted for age, sex, geographic region, and baseline comorbidities. Results: The study included 36,427 patients: 13,456 apixaban (37%) and 22,971 warfarin (63%); among whom 10,671 (79%) apixaban an...
GYHL: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. GYHL is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899871. Others: None declared.